Download
12885_2024_Article_12204.pdf 1,82MB
WeightNameValue
1000 Titel
  • Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany
1000 Autor/in
  1. Luna, Jaime |
  2. Picker, Nils |
  3. Wilke, Thomas |
  4. Lutz, Magnus |
  5. Hess, Juergen |
  6. , Bernhard |
  7. Xiong, Yan |
  8. Götze, Thorsten Oliver |
1000 Verlag
  • BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-13
1000 Erschienen in
1000 Quellenangabe
  • 24(1):462
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-024-12204-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016202/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Patients with metastatic gastric cancer (mGC) have poor prognosis. This real-world study aimed to describe treatment regimens and survival of mGC patients.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>A retrospective analysis was conducted using anonymized German claims data (AOK PLUS) covering a period from 2010 to 2021. The study population included newly diagnosed mGC cases identified from 2011 to 2020. The index date was defined as the first diagnosis of metastasis on or after gastric cancer diagnosis. Therapy regimens were identified based on inpatient and outpatient data, and subsequently stratified by line of treatment. Survival analyses were conducted using the Kaplan–Meier method.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The cohort consisted of 5,278 mGC incident cases (mean age: 72.7 years; male: 61.9%). Nearly half of the incident cases received mGC-related treatment (49.8%). Treated patients were more often male, younger, and had fewer comorbidities compared to untreated patients. Of the 2,629 mGC patients who started the first line of treatment (1LOT), 32.8% switched to 2LOT, and 10.2% reached 3LOT. Longer survival time was observed among disease-specific treated cases compared with untreated cases (median real-world overall survival (rwOS): 12.7 months [95%CI 12.1 – 13.3 months] vs. 3.7 months [95%CI 3.4 – 4.0 months]).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Systemic therapy was not received in almost half of the mGC patients. In those patients, a very short median rwOS was observed. Treatment patterns were generally in line with the guideline recommendations, however, therapy switching rates and poor prognosis indicate high unmet needs also in the treated population.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Cohort
lokal Metastatic Gastric Cancer
lokal Aged [MeSH]
lokal Stomach Neoplasms/therapy [MeSH]
lokal Humans [MeSH]
lokal Real-world evidence
lokal Germany
lokal Retrospective Studies [MeSH]
lokal Germany/epidemiology [MeSH]
lokal Survival
lokal Outpatients [MeSH]
lokal Male [MeSH]
lokal Splenic Neoplasms [MeSH]
lokal Research
lokal Treatment
lokal Stomach Neoplasms/epidemiology [MeSH]
lokal Inpatients [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-5990-7534|https://orcid.org/0000-0001-5328-4332|https://frl.publisso.de/adhoc/uri/V2lsa2UsIFRob21hcw==|https://orcid.org/0000-0002-8930-5243|https://orcid.org/0009-0006-7568-4330|https://orcid.org/0000-0002-8643-4170|https://orcid.org/0000-0003-1212-5516|https://frl.publisso.de/adhoc/uri/R8O2dHplLCBUaG9yc3RlbiBPbGl2ZXI=
1000 Hinweis
  • DeepGreen-ID: 14970113597a49f994013c217aa73123 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Daiichi Sankyo Deutschland GmbH |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Daiichi Sankyo Deutschland GmbH |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6522627.rdf
1000 Erstellt am 2025-07-06T16:00:56.894+0200
1000 Erstellt von 322
1000 beschreibt frl:6522627
1000 Zuletzt bearbeitet 2025-07-29T23:15:59.535+0200
1000 Objekt bearb. Tue Jul 29 23:15:59 CEST 2025
1000 Vgl. frl:6522627
1000 Oai Id
  1. oai:frl.publisso.de:frl:6522627 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source